|Articles|September 26, 2014

EFPIA Promises Stronger Ties with China

The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”. Federation delegates are this week concluding a visit to Beijing to establish “a better understanding of the numerous healthcare reforms underway in China … and explore closer paths of cooperation in global drug development between China and Europe”.

The EFPIA delegation included global CEOs, EFPIA Director General Richard Bergstrom, and EFPIA President and Sanofi CEO, Chris Viehbacher. The delegates have taken part in a series of events in Beijing, including a conference on Translational Medicine and a workshop on Transparency and Good Governance.

Viehbacher commented: “EFPIA is committed to fostering productive relations with China… The research-based pharmaceutical industry is a global industry, and this visit marks an important milestone in fostering understanding between international health care leaders and promoting awareness about the advancements taking place in China’s life sciences sector.”


Related to this article

Pharmaceutical Executive daily
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
Pharmaceutical executive daily
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.